{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:25:45Z","timestamp":1787570745677,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Motivation<\/jats:title>\n                    <jats:p>Cell-free DNA (cfDNA) whole-genome sequencing (WGS) is a promising approach for detecting cancer recurrence. It enables cancer detection by identifying all tumor-derived cfDNA (ctDNA) molecules carrying somatic single nucleotide variants (sSNVs). While ideally, a sequencing platform should be highly accurate for reliable ctDNA detection, in reality, all sequencing platforms introduce sequencing errors that generate false positives indistinguishable from true SNVs. Understanding how sequencing parameters influence ctDNA detection sensitivity at low tumor fractions (TFs) in cfDNA samples is essential for guiding sequencing strategies in clinical contexts. To model cfDNA sequencing for tumor detection, which contains asymmetric noise and multiple interacting parameters, analytical modeling is intractable, motivating large-scale parallelized simulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We developed a simulation framework to generate in silico cfDNA data across 10 cancer types. In total, 480 million cfDNA samples were simulated from tumor WGS profiles. Overall, the lowest detectable TF differs substantially between cancer types under identical sequencing conditions due to variations in mutational load. For cancers with high mutational load, 3\u00d7 coverage with low-error techniques reliably detects TFs below 0.1%. In contrast, cancers with low mutational load require at least six-fold higher coverage to achieve comparable detection thresholds. Increasing sequencing quality scores from Q30 to Q55 at 30\u00d7 coverage further enhances sensitivity, enabling detection of TFs as low as 1\u2009\u00d7\u200910\u22125. This study provides a comprehensive framework for optimizing sequencing parameters, offering valuable guidance for tailoring future technology development for specific cancer types and clinical applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Availability and implementation<\/jats:title>\n                    <jats:p>The code is publicly available at https:\/\/github.com\/UMCUGenetics\/cfdetect\/tree\/main.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bioinformatics\/btag460","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:57:22Z","timestamp":1782860242000},"source":"Crossref","is-referenced-by-count":0,"title":["Large-scale simulation of coverage and error rate tradeoffs for cancer detection in cell-free DNA whole-genome sequencing"],"prefix":"10.1093","volume":"42","author":[{"given":"Li-Ting","family":"Chen","sequence":"first","affiliation":[{"name":"Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University , Utrecht 3584 CX,","place":["The Netherlands"]},{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht 3584 CS,","place":["The Netherlands"]},{"name":"Oncode Institute , Utrecht 3521 AL,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University , Utrecht 3584 CX,","place":["The Netherlands"]},{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht 3584 CS,","place":["The Netherlands"]},{"name":"Oncode Institute , Utrecht 3521 AL,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe","family":"Jager","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University , Utrecht 3584 CX,","place":["The Netherlands"]},{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht 3584 CS,","place":["The Netherlands"]},{"name":"Oncode Institute , Utrecht 3521 AL,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026082407033874000_btag460-B1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41419-019-1770-3","article-title":"Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study","volume":"10","author":"Alborelli","year":"2019","journal-title":"Cell Death Dis"},{"key":"2026082407033874000_btag460-B2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"2026082407033874000_btag460-B3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology"},{"key":"2026082407033874000_btag460-B4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.ajpath.2022.07.007","article-title":"Circulating tumor DNA allele fraction: a candidate biological signal for multicancer early detection tests to assess the clinical significance of cancers","volume":"192","author":"Bredno","year":"2022","journal-title":"Am J Pathol"},{"key":"2026082407033874000_btag460-B5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1101\/gr.279144.124","article-title":"Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling","volume":"35","author":"Chen","year":"2025","journal-title":"Genome Res"},{"key":"2026082407033874000_btag460-B6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","article-title":"Cell-free DNA analysis in current cancer clinical trials: a review","volume":"126","author":"Cisneros-Villanueva","year":"2022","journal-title":"Br J Cancer"},{"key":"2026082407033874000_btag460-B7","doi-asserted-by":"crossref","first-page":"eaay9040","DOI":"10.1126\/science.aay9040","article-title":"Early detection of cancer","volume":"375","author":"Crosby","year":"2022","journal-title":"Science"},{"key":"2026082407033874000_btag460-B8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2026082407033874000_btag460-B9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","journal-title":"Nature"},{"key":"2026082407033874000_btag460-B10","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2026082407033874000_btag460-B11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s12864-024-10440-w","article-title":"Sequencing accuracy and systematic errors of nanopore direct RNA sequencing","volume":"25","author":"Liu-Wei","year":"2024","journal-title":"BMC Genomics"},{"key":"2026082407033874000_btag460-B12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41586-023-06054-z","article-title":"Pan-cancer whole-genome comparison of primary and metastatic solid tumours","volume":"618","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nature"},{"key":"2026082407033874000_btag460-B13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"2026082407033874000_btag460-B14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12885-016-2164-x","article-title":"Differences in predictions of ODE models of tumor growth: a cautionary example","volume":"16","author":"Murphy","year":"2016","journal-title":"BMC Cancer"},{"key":"2026082407033874000_btag460-B15","author":"Oxford Nanopore Technologies plc"},{"key":"2026082407033874000_btag460-B16","author":"Illumina, Inc"},{"key":"2026082407033874000_btag460-B17","author":"Pacific Biosciences of California, Inc. Onso System Specification Sheet","year":"2023"},{"key":"2026082407033874000_btag460-B18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"2026082407033874000_btag460-B19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ccell.2019.09.003","article-title":"Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA","volume":"36","author":"van der Pol","year":"2019","journal-title":"Cancer Cell"},{"key":"2026082407033874000_btag460-B20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"2026082407033874000_btag460-B21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jmoldx.2021.04.011","article-title":"Clinical validation of whole genome sequencing for cancer diagnostics","volume":"23","author":"Roepman","year":"2021","journal-title":"J Mol Diagn"},{"key":"2026082407033874000_btag460-B22","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"2026082407033874000_btag460-B23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-020-01182-9","article-title":"The distribution of cellular turnover in the human body","volume":"27","author":"Sender","year":"2021","journal-title":"Nat Med"},{"key":"2026082407033874000_btag460-B24","author":"Roche. Sequencing by Expansion (SBX)\/AGBT","year":"2025"},{"key":"2026082407033874000_btag460-B25","doi-asserted-by":"crossref","first-page":"lqab019","DOI":"10.1093\/nargab\/lqab019","article-title":"Sequencing error profiles of Illumina sequencing instruments","volume":"3","author":"Stoler","year":"2021","journal-title":"NAR Genom Bioinform"},{"key":"2026082407033874000_btag460-B8044301"},{"key":"2026082407033874000_btag460-B26","author":"Ultima Genomics, Inc","year":"2025"},{"key":"2026082407033874000_btag460-B27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/42\/Supplement_2\/btag460\/70726064\/btag460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/42\/Supplement_2\/btag460\/70726064\/btag460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:03:44Z","timestamp":1787569424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/doi\/10.1093\/bioinformatics\/btag460\/8767310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":28,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/btag460","relation":{},"ISSN":["1367-4803","1367-4811"],"issn-type":[{"value":"1367-4803","type":"print"},{"value":"1367-4811","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]},"article-number":"btag460"}}